Bausch Health
About: Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Employees: 20,700
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 24
7% more funds holding
Funds holding: 208 [Q3] → 223 (+15) [Q4]
0.4% less ownership
Funds ownership: 69.27% [Q3] → 68.86% (-0.4%) [Q4]
4% less capital invested
Capital invested by funds: $2.08B [Q3] → $1.99B (-$86.1M) [Q4]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 7 (-1) [Q4]
30% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 74
58% less call options, than puts
Call options by funds: $37.8M | Put options by funds: $89.1M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$8
51%
upside
Avg. target
$8
51%
upside
High target
$8
51%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Jefferies David Steinberg 0 / 0 met price target | 51%upside $8 | Hold Downgraded | 6 Feb 2025 |
Financial journalist opinion
Based on 18 articles about BHC published over the past 30 days
Positive
Zacks Investment Research
5 hours ago
Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
6 hours ago
Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates
Bausch Health (BHC) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.59 per share a year ago.
Neutral
Seeking Alpha
7 hours ago
Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript
Bausch Health Companies Inc. (NYSE:BHC ) Q1 2025 Earnings Conference Call April 30, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Nedelcovych - TD Cowen Jason Gerberry - Bank of America Michael Freeman - Raymond James Operator Greetings. Welcome to the Bausch Health First Quarter 2025 Earnings Call.
Neutral
Accesswire
11 hours ago
Bausch Health Announces First Quarter 2025 Results
First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health Companies of $58 million and GAAP Net Loss of $86 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies (non-GAAP) 1 of $661 million, in line with prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2025 RESULTS Eighth consecutive quarter of year-over-year Revenue and Adjusted EBITDA (non-GAAP) 1 growth, with 6% and 14% growth versus the prior year period, respectively With strong financial momentum, remain committed to evaluating all options to unlock shareholder value, including maximizing the value of assets and share buybacks Successfully completed $7.9B refinancing in early April to extend near- and medium- term maturities Received favorable ruling from D.C. District Court in Norwich's case against the FDA Maintaining full-year 2025 Revenue and Adjusted EBITDA (non-GAAP) 1 guidance, with Adjusted Cash Flow from Operations (non-GAAP) 1 guidance updated primarily to reflect higher interest expense LAVAL, QC / ACCESS Newswire / April 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2025 financial results and other key updates from the quarter.
Neutral
Accesswire
1 day ago
Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System
A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, announced today that Health Canada has granted medical device license clearance for Thermage® FLX, the latest generation of the globally-recognized Thermage® system for non-invasive skin tightening and contouring. "The clearance of Thermage FLX in Canada is a positive development for our company and important for the continued growth of our aesthetic business", said Thomas J.
Positive
Zacks Investment Research
6 days ago
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Positive
Zacks Investment Research
1 week ago
Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
WSJ
1 week ago
Bausch Health Learns Icahn Has 34% Economic Interest in Shares
Activist investor Carl Icahn has tightened his hold on pharmaceutical company Bausch Health.
Positive
Reuters
1 week ago
Bausch Health says Carl Icahn has exposure to about 34% of company's shares
Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare firm said in a filing on Tuesday.
Neutral
Accesswire
1 week ago
Bausch Health Announces Filing of Supplement to Proxy Statement
Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares LAVAL, QC / ACCESS Newswire / April 22, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX: BHC) (the "Company" or "Bausch Health") today announced that it has filed a supplement (the "Proxy Statement Supplement") to its proxy statement dated April 2, 2025 (the "Proxy Statement") in respect of the Company's upcoming annual general meeting of shareholders on May 13, 2025. The Company is updating the Proxy Statement to disclose, in addition to the 34,721,118 common shares reported as being beneficially owned (9.4%), Mr.
Charts implemented using Lightweight Charts™